0.31
0.31 (-1.09%)
As of Sep 16, 2022
Tyme Technologies, Inc. [TYME]
Source:
Company Overview
TYME is an emerging biotechnology company developing CMBTs that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Companys therapeutic approach is designed to take advantage of a cancer cells innate metabolic requirements to cause cancer cell death.
| Country | United States |
| Headquarters | bedminster, new jersey |
| Phone Number | 212-461-2315 |
| Industry | manufacturing |
| CEO | Richard Cunningham |
| Website | tymeinc.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-6.6 |
| Net Income | $-6.5 |
| Net Cash | $-7.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -16.2% |
| Profit as % of Stockholder Equity | -8.8% |
Management Effectiveness
| Return on Equity | -8.8% |
| Return on Assets | -8.1% |
| Turnover Ratio | |
| EBITA | $-6.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $80.2 |
| Total Liabilities | $6 |
| Operating Cash Flow | $-4.8 |
| Investing Cash Flow | $-2.5 |
| Financing Cash Flow | $0 |
